Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
Study represents first inclusion
of Volcano Revolution® 45
MHz IVUS Imaging Catheter in large-scale pharmaceutical plaque progression
trial
|
|
May 5, 2008 -- San Diego --
Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer
of intravascular ultrasound (IVUS), functional measurement (FM) and
Optical Coherence Tomography (OCT) products designed to enhance the
diagnosis and treatment of coronary and peripheral vascular disease,
announced today participation in SATURN (Study of Coronary Atheroma
by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN).
This marks the first major pharmaceutical
trial allowing physicians to use the Volcano Revolution® 45 MHz IVUS Imaging catheter as part
of the protocol.
SATURN is a 104-week, parallel-group, multicentre,
double-blind, Phase IIIb intravascular ultrasound (IVUS) imaging
study of approximately 1,300 patients at 170 centres
worldwide.
Intravascular
Ultrasound |
|
This study by AstraZeneca
is designed to measure the impact of CRESTOR™ (rosuvastatin) 40
mg and atorvastatin (Lipitor®) 80 mg on the progression of atherosclerosis
in high risk patients. SATURN will compare the effects of these
two statins on the ability to decrease progression or induce
regression of atherosclerosis, the main cause of cardiovascular
disease, following two years of treatment in patients with coronary
artery disease.
The SATURN study is chaired by Steve Nissen, M.D.,
with Steve Nichols, M.D. from the Cleveland Clinic Core Lab as
the principal investigator. Under this protocol, physicians enrolling
patients may select the Volcano Revolution® IVUS catheters as
their IVUS catheter of choice. |
About Volcano Corporation
Volcano Corporation (NASDAQ: VOLC) offers a broad suite of devices
designed to facilitate endovascular procedures, enhance the diagnosis
of vascular and structural heart diseases and guide optimal therapies.
The company's intravascular ultrasound (IVUS) product line includes
ultrasound consoles that can be integrated directly into virtually
any modern cath lab. Volcano IVUS offers unique features, including
both single-use phased array and rotational IVUS imaging catheters,
and advanced functionality options such as VH™ tissue characterization and ChromaFlo®.
Internal DICOM networking provided by DICOM by Merge. Volcano also
provides functional measurement (FM) consoles and single-use pressure
and flow guide wires and is developing a line of ultra high-resolution
Optical Coherence Tomography systems and catheters. Currently, more
than 3,200 Volcano IVUS and FM systems are installed worldwide, with
approximately half of its revenues coming from outside the United States.
For more information, visit the company's website at http://www.volcanocorp.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the U.S. Private Securities Litigation Reform Act of 1995. Any statements
in this press release regarding Volcano's business that are not historical
facts may be considered "forward-looking statements," including statements
regarding the company's success and timing of product development and
new product introductions, and market penetration, conditions and expectations.
Forward-looking statements are based on management's current, preliminary
expectations and are subject to risks and uncertainties, which may
cause Volcano's results to differ materially and adversely from the
statements contained herein. Some of the potential risks and uncertainties
that could cause actual results to differ from the results predicted
are detailed in the company's annual report on Form 10-K, quarterly
report on Form 10-Q, and other filings made with the Securities and
Exchange Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. Volcano
undertakes no obligation to update any forward- looking statements
to reflect new information, events or circumstances after the date
they were made, or to reflect the occurrence of unanticipated events.
Source: Volcano Corporation |